Overactivated neddylation pathway as a therapeutic target in lung cancer

Journal of the National Cancer Institute

Volumn 106, Issue 6, 2014, Pages

  Li, Lihui ^a,b,c   Wang, Mingsong ^e   Yu, Guangyang ^a,b,c   Chen, Ping ^a,b,f   Li, Hui ^g   Wei, Dongping ^a,b   Zhu, Ji ^a   Xie, Li ^a   Jia, Huixun ^a   Shi, Jieyi ^d   Li, Chunjie ^a,b,c   Yao, Wantong ^a,b,c   Wang, Yanchun ^b,c   Gao, Qiang ^d   Jeong, Lak Shin ^h,i   Lee, Hyuk Woo ⁱ   Yu, Jinha ⁱ   Hu, Fengqing ^e   Mei, Ju ^e   Wang, Ping ^g   Chu, Yiwei ^c   Qi, Hui ^j   Yang, Meng ^j,m   Dong, Ziming ^f   Sun, Yi ^k   Hoffman, Robert M ^l,m   Jia, Lijun ^a,b,c   more..

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c Institute of Pathogenic Biology   (China)

^d FUDAN UNIVERSITY   (China)

^e XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f ZHENGZHOU UNIVERSITY   (China)

^g EAST CHINA NORMAL UNIVERSITY   (China)

^h Seoul National University   (South Korea)

ⁱ Ewha Womans University   (South Korea)

^j AntiCancer Beijing Co Ltd   (China)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^m ANTICANCER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CULLIN; ENZYME; NEDD8 ACTIVATING ENZYME; NEDD8 CONJUGATING ENZYME; NEDD8 PROTEIN; PEVONEDISTAT; PROTEIN NOXA; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D) PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ((1S,2S,4R) 4 (4 ((1S) 2,3 DIHYDRO 1H INDEN 1 YLAMINO) 7H PYRROLO(2,3 D)PYRIMIDIN 7 YL) 2 HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ANTINEOPLASTIC AGENT; CYCLOPENTANE DERIVATIVE; NEDD8 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; UBIQUITIN;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL AGING; CELL CLONE; CELL FATE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CANCER CELL LINE; LUNG CARCINOGENESIS; LUNG METASTASIS; LUNG SQUAMOUS CELL CARCINOMA; MIGRATION INHIBITION; NEDDYLATION; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; ADENOCARCINOMA; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLOPENTANES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY; UBIQUITINS;

EID: 84905164592     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju083     Document Type: Article

References (47)

1. Xirodimas D P. Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochem Soc Trans. 2008;36(Pt 5):802-806.
2. Xirodimas D P, Saville MK, Bourdon JC, et al. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell. 2004;118(1):83-97.
3. Zuo W, Huang F, Chiang YJ, et al. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-beta type II receptor. Mol Cell. 2013;49(3):499-510.
4. Loftus SJ, Liu G, Carr SM, et al. NEDDylation regulates E2F-1-dependent transcription. EMBO Rep. 2012;13(9):811-818.
5. Sakata E, Yamaguchi Y, Miyauchi Y, et al. Direct interactions between NEDD8 and ubiquitin E2 conjugating enzymes upregulate cullin-based E3 ligase activity. Nat Struct Mol Biol. 2007;14(2):167-168.
6. Wu JT, Lin HC, Hu YC, et al. Neddylation and deneddylation regulate Cul1 and Cul3 protein accumulation. Nat Cell Biol. 2005;7(10):1014-1020.
7. Saha A, Deshaies RJ. Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell. 2008;32(1):21-31.
8. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiq-uitin ligases. Nat Rev Mol Cell Biol. 2005;6(1):9-20.
9. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteas-ome system. Nat Rev Drug Discov. 2006;5(7):596-613.
10. McLarnon A. Cancer: Mdm2-regulated stabilization of HuR by neddyla-tion in HCC and colon cancer-a possible target for therapy. Nat Rev Gastroenterol Hepatol. 2011;9(1):4.
11. Embade N, Fernandez-Ramos D, Varela-Rey M, et al. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology. 2012;55(4):1237-48.
12. Xirodimas D P, Sundqvist A, Nakamura A, et al. Ribosomal proteins are targets for the NEDD8 pathway. EMBO Rep. 2008;9(3):280-286.
13. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732-736.
14. Soucy TA, Dick LR, Smith PG, et al. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer. 2010;1(7):708-716.
15. Luo Z, Yu G, Lee HW, et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 2012;72(13):3360-3371.
16. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia. 2011;13(6):561-569.
17. Milhollen MA, Traore T, Adams-Duffy J, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood. 2010;116(9):1515-1523.
18. Blank JL, Liu XJ, Cosmopoulos K, et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res. 2013;73(1):225-234.
19. Mackintosh C, Garcia-Dominguez DJ, Ordonez JL, et al. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene. 2013;32(11):1441-1451.
20. Lin JJ, Milhollen MA, Smith PG, et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 2010;70(24):10310-10320.
21. Zhao Y, Xiong X, Jia L, et al. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis. 2012;3:e386. doi:10.1038/cddis.2012.125.
22. Wei D, Li H, Yu J, et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res. 2012;72(1):282-293.
23. Yang D, Tan M, Wang G, et al. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One. 2012;7(3):e34079.
24. Kee Y, Huang M, Chang S, et al. Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol Cancer Res. 2012;10(3):369-377.
25. Tanaka T, Nakatani T, Kamitani T. Negative regulation of NEDD8 conjugation pathway by novel molecules and agents for anticancer therapy. Curr Pharm Des. 2013;19(22):4131-4139.
26. Cooper WA, Lam DC, O'Toole SA, et al. Molecular biology of lung cancer. J Thorac Dis. 2013;5(Suppl 5):S479-S490.
27. Powell CA, Halmos B, Nana-Sinkam S P. Update in lung cancer and meso-thelioma 2012. Am J Respir Crit Care Med. 2013;188(2):157-166.
28. Nana-Sinkam S P, Powell CA. Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e30S-39S.
29. Lee HW, Nam SK, Choi WJ, et al. Stereoselective synthesis of MLN4924, an inhibitor of NEDD8-activating enzyme. J Org Chem. 2011;76(9):3557-3561.
30. Yang D, Li L, Liu H, et al. Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. Cell Death Differ. 2013;20(2):235-247.
31. Wang R, Wang Y, Liu N, et al. FBW7 regulates endothelial functions by targeting KLF2 for ubiquitination and degradation. Cell Res. 2013;23(6):803-819.
32. Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apop-tosis, and senescence. Cancer Res. 2009;69(12):4974-4982.
33. Kurz T, Chou YC, Willems AR, et al. Dcn1 functions as a scaffold-type E3 ligase for cullin neddylation. Mol Cell. 2008;29(1):23-35.
34. Kurz T, Ozlu N, Rudolf F, et al. The conserved protein DCN-1/Dcn1p is required for cullin neddylation in C. elegans and S. cerevisiae. Nature. 2005;435(7046):1257-1261.
35. Morimoto M, Nishida T, Nagayama Y, et al. Nedd8-modification of Cul1 is promoted by Roc1 as a Nedd8-E3 ligase and regulates its stability. Biochem Biophys Res Commun. 2003;301(2):392-398.
36. Sarkaria I, O-charoenrat P, Talbot SG, et al. Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. Cancer Res. 2006;66(19):9437-9444.
37. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847-857.
38. Lwin Z, Riess JW, Gandara D. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis. 2013;5(Suppl 5):S556-S564.
39. Lin HK, Chen Z, Wang G, et al. Skp2 targeting suppresses tumo-rigenesis by Arf-p53-independent cellular senescence. Nature. 2010;464(7287):374-379.
40. Chan CH, Morrow JK, Li CF, et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013;154(3):556-568.
41. Jia L, Yang J, Hao X, et al. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin Cancer Res. 2010;16(3):814-824.
42. Lee MH, Zhao R, Phan L, et al. Roles of COP9 signalosome in cancer. Cell Cycle. 2011;10(18):3057-3066.
43. Liu S, Yang H, Zhao J, et al. NEDD8 ultimate buster-1 long (NUB1L) protein promotes transfer of NEDD8 to proteasome for degradation through the P97UFD1/NPL4 complex. J Biol Chem. 2013;288(43):31339-31349.
44. Tanaka T, Kawashima H, Yeh ET, et al. Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L. J Biol Chem. 2003;278(35):32905-32913.
45. Kamitani T, Kito K, Fukuda-Kamitani T, et al. Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1. J Biol Chem. 2001;276(49):46655-46660.
46. Toth JI, Yang L, Dahl R, et al. A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. Cell Rep. 2012;1(4):309-316.
47. Milhollen MA, Thomas M P, Narayanan U, et al. Treatment-emergent mutations in NAEbeta confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell. 2012;21(3):388-401.